Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
HeartBeat.bio AG logo — REINVENTING CARDIAC DRUG DISCOVERY

HeartBeat.bio AG

REINVENTING CARDIAC DRUG DISCOVERY

Founded 2021 Austria Austria 22 employees Seed Total: $6.00M Biotechnology

General Information

Company Name HeartBeat.bio AG
Founded Year 2021
Location Austria Austria +1
Employees 22
Industries Biotechnology
Funding Stage Seed
Social

Get notified when HeartBeat.bio AG moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About HeartBeat.bio AG

HeartBeat.bio AG is a biotechnology startup that aims to reinvent cardiac drug discovery through its innovative approach. The company, founded in 2021 and headquartered in Austria, is focusing on the development of a high-throughput human organoid cultivation, screening, and AI-supported data analysis solution. Its Cardioid Drug Discovery Platform, based on technology from the Institute of Molecular Biotechnology (IMBA), utilizes self-assembling cardiac organoids to model heart diseases, providing a unique in-vitro system for drug development. With a recent €4.50M Seed Round investment from aws Gründerfonds, i&I Bio, Invest AG, and Tensor Ventures in 02 November 2023, HeartBeat.bio is well-positioned to advance its groundbreaking approach to revolutionize the treatment of heart failure and related conditions.

Taxonomy: Cardiac Organoids, Drug Discovery, Heart Failure, Cardiomyopathy, Myocardial Infarction, 3D Disease Modelling, High-Throughput Screening, Cardiovascular Regeneration, Cardiotoxicity, Cardio-Oncology, iPS Cells, AI-supported Analysis, Genetic Cardiomyopathies, Vienna BioCenter

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round •••••• 4
Investor Investor Investor
•••• •••• 		02 Nov 2023
Seed Round •••••• 1 •••• •••• 04 May 2021

HeartBeat.bio AG Alternatives & Competitors

HeartBeat.bio AG vs
HeartBeat.bio
HeartBeat.bio

HeartBeat.bio develops 3D screening platform for heart failure and cardiomyopathy using self-organiz...

HeartBeat.bio AG vs
Rejuvenate Biomed
Rejuvenate Biomed Belgium

We envision a future where people stay healthy for life

Series B
15 employees
HeartBeat.bio AG vs
myotwin
myotwin Germany

For a better and animal-free drug development

9 employees

FAQ About HeartBeat.bio AG

REINVENTING CARDIAC DRUG DISCOVERY
HeartBeat.bio AG was founded in 2021.
HeartBeat.bio AG is headquartered in Austria.
HeartBeat.bio AG operates in the following industries: Biotechnology.
HeartBeat.bio AG has approximately 22 employees.
HeartBeat.bio AG has completed 2 funding rounds, raising a total of $6.00M. The latest funding stage is Seed.
Top alternatives and competitors to HeartBeat.bio AG include HeartBeat.bio, Rejuvenate Biomed, myotwin, StemoniX, NeuCyte. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
HeartBeat.bio AG and HeartBeat.bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors HeartBeat.bio AG and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy